Previous close | 15.90 |
Open | 15.85 |
Bid | 0.00 x 12000 |
Ask | 0.00 x 12000 |
Day's range | 15.85 - 15.90 |
52-week range | 15.31 - 49.99 |
Volume | |
Avg. volume | 103 |
Market cap | 1.075B |
Beta (5Y monthly) | 0.80 |
PE ratio (TTM) | N/A |
EPS (TTM) | -9.91 |
Earnings date | 07 May 2024 - 13 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 22.80 |
SOMERVILLE, Mass., April 11, 2024--bluebird bio, Inc. (Nasdaq: BLUE) today announced that the Compensation Committee of the Company’s Board of Directors approved inducement grants of 102,700 restricted stock units ("RSUs") to twelve newly hired employees with a grant date of April 9, 2024 (the "Inducement Grants"). The Inducement Grants are subject to the terms and conditions of award agreements covering the grants and the Company’s 2021 Inducement Plan.
SOMERVILLE, Mass., March 26, 2024--bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird bio" or the "Company") today reported fourth quarter and annual financial results and business highlights for the year ended December 31, 2023, including recent commercial and operational progress.
SOMERVILLE, Mass., March 25, 2024--bluebird bio, Inc. (Nasdaq: BLUE) announced today that it will host a conference call to discuss fourth quarter and 2023 annual results and business updates on March 26, 2024, at 8:00 a.m. ET.